Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.

November 20, 2023 updated by: Sofia Straudi, University Hospital of Ferrara

The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial.

Multiple Sclerosis (MS) is often characterized by the presence of balance and cognitive impairments. Cognitive functions play a key role in balance control. Simultaneously performing cognitive tasks decreases walking and balance ability (Dual-Task cost). Rehabilitative treatment of patients with MS does not have to consider separately the motor and cognitive aspects. Video-Game Therapy (VGT) is a novel tool that allows a multimodal training approach. VGT typically provides augmented feedback during training that can contribute to learning motor skills. The main objective of this exploratory study will be to test the effects of a commercially available VGT on balance and cognitive function in ambulatory MS patients compared to a standardized balance platform training (BPT). Secondary, we will explore the effects of VGT and BPT on other domains that are usually impaired in MS population and that can be improved by motor rehabilitation, such as psychological well-being, fatigue and Quality of Life.

Study Overview

Study Type

Interventional

Enrollment (Actual)

48

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Ferrara, Italy, 44124
        • Ferrara University Hospital
    • Emilia Romagna
      • Ferrara, Emilia Romagna, Italy, 44124
        • Sofia Straudi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • diagnosis of MS (primary or secondary progressive, relapsing-remitting), without relapses in the preceding 3 months
  • mild to moderate balance impairments with increased fall risk, defined as TUG > 8.4s
  • disability rate definited by Kurtzke Expanded Disability Status Scale (EDSS) score from 4 to 5.5,

Exclusion Criteria:

  • other conditions that may affect motor function
  • impaired cognitive functioning (Mini Mental Status Examination score less than 24)
  • visual impairments (daltonism and visual acuity deficit)
  • medical conditions that might interfere with the ability to complete the study protocol safely.

A group of healthy subjects matched for age and sex will be involved for a comparison on the instrumental data (force platforms).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Video game therapy
Subjects belonging to the experimental group will receive a Video Game Therapy (VGT) protocol using the Xbox console. They will receive 12 sessions of treatment within 4 weeks (3 sessions per week); each session will last 1 hour. To manage possible absence lasting one or more treatment sessions, a potential window of 5 weeks will be set to ensure the achievement of all 12 sessions. Will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling
Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
Active Comparator: Balance platform therapy
Subjects belonging to the control group will receive the same amount of therapy (12 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an "entry level," and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback.
Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Timed Up and Go (TUG) test
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
TUG measures balance and functional mobility.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Four Square Step Test (FSST)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The FSST is a timed test, intended to challenge the rapid change in direction while stepping forward, backward and sideways over a low obstacle.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Functional Reach Test (FRT)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The FRT assesses the subject's stability by measuring the maximum distance an individual can reach forward while standing in a fixed position.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Dynamic Gait Index (DGI)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Clinical tool to assess gait, balance and risk of fall.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Modified Fatigue Impact Scale (MFIS)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Questionnaire which evaluates the perceived impact of fatigue on the subscales physical, cognitive and psychosocial functioning.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Multiple Sclerosis Walking Scale-12 (MSWS-12)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
This questionnaire assesses the impact of MS on walking ability.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Multiple Sclerosis Impact Scale-29 (MSIS-29)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
This is an health-rated quality of life questionnaire that assesses the impact of MS on physical and psychological functions.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Beck Depression Inventory-Second Edition (BDI-II)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
This is a 21-item self-report instrument that serves to assess depression severity
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
State Trait Anxiety Inventory (STAI-Y)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
STAI-Y is an easy-to-use and interpretative tool to detect and measure anxiety.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Go-No Go - Test of Attentional Performance T.A.P.
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Go-No Go task examine the specific capacity to suppress an inadequate reaction.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Test of Attentional Performance T.A.P.
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
In this task divided attention can be explored with computerized "dual-task" test where two stimuli (visual and acoustic) are required simultaneously
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Stroop Color-Word Test (SCWT)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The SCWT explores sustained attention and some aspects of executive function.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Symbol Digit Modalities Test (SDMT)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The SDMT consists of orally substituting a number for a pseudorandom sequence of geometric figures as quickly as possible for testing executive functions.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Instrumented Basic Balance Evaluation (IBBE)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Force platform measurement are used as objective markers of subjects' balance ability.
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Instrumented Dual Task (IDT)
Time Frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Dual cognitive-motor tasks are often used in clinical practice to evaluate the interaction between patients' cognitive and motor ability .
Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Sofia Straudi, MD, PhD, Ferrara Rehabilitation Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2017

Primary Completion (Actual)

October 1, 2022

Study Completion (Actual)

October 1, 2022

Study Registration Dates

First Submitted

November 16, 2017

First Submitted That Met QC Criteria

November 21, 2017

First Posted (Actual)

November 27, 2017

Study Record Updates

Last Update Posted (Actual)

November 22, 2023

Last Update Submitted That Met QC Criteria

November 20, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on Video game therapy

3
Subscribe